These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28344999)

  • 1. Long-Term Engraftment and Fetal Globin Induction upon
    Chang KH; Smith SE; Sullivan T; Chen K; Zhou Q; West JA; Liu M; Liu Y; Vieira BF; Sun C; Hong VP; Zhang M; Yang X; Reik A; Urnov FD; Rebar EJ; Holmes MC; Danos O; Jiang H; Tan S
    Mol Ther Methods Clin Dev; 2017 Mar; 4():137-148. PubMed ID: 28344999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major.
    Psatha N; Reik A; Phelps S; Zhou Y; Dalas D; Yannaki E; Levasseur DN; Urnov FD; Holmes MC; Papayannopoulou T
    Mol Ther Methods Clin Dev; 2018 Sep; 10():313-326. PubMed ID: 30182035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.
    Demirci S; Zeng J; Wu Y; Uchida N; Shen AH; Pellin D; Gamer J; Yapundich M; Drysdale C; Bonanno J; Bonifacino AC; Krouse AE; Linde NS; Engels T; Donahue RE; Haro-Mora JJ; Leonard A; Nassehi T; Luk K; Porter SN; Lazzarotto CR; Tsai SQ; Weiss MJ; Pruett-Miller SM; Wolfe SA; Bauer DE; Tisdale JF
    J Clin Invest; 2020 Dec; 130(12):6677-6687. PubMed ID: 32897878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression.
    Rajendiran V; Devaraju N; Haddad M; Ravi NS; Panigrahi L; Paul J; Gopalakrishnan C; Wyman S; Ariudainambi K; Mahalingam G; Periyasami Y; Prasad K; George A; Sukumaran D; Gopinathan S; Pai AA; Nakamura Y; Balasubramanian P; Ramalingam R; Thangavel S; Velayudhan SR; Corn JE; Mackay JP; Marepally S; Srivastava A; Crossley M; Mohankumar KM
    Mol Ther; 2024 Mar; 32(3):663-677. PubMed ID: 38273654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional Repressor BCL11A in Erythroid Cells.
    Zheng G; Orkin SH
    Adv Exp Med Biol; 2024; 1459():199-215. PubMed ID: 39017845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34
    Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ
    Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
    Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
    Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of CRISPR/Cas9-Mediated Fetal Hemoglobin Reactivation in Erythroblasts Derived from Cord Blood-Hematopoietic Stem Cells.
    Maroofi N; Maleki MSM; Tahmasebi M; Khorshid HRK; Modaberi Y; Najafipour R; Banan M
    Mol Biotechnol; 2024 Apr; ():. PubMed ID: 38649638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease.
    Lessard S; Rimmelé P; Ling H; Moran K; Vieira B; Lin YD; Rajani GM; Hong V; Reik A; Boismenu R; Hsu B; Chen M; Cockroft BM; Uchida N; Tisdale J; Alavi A; Krishnamurti L; Abedi M; Galeon I; Reiner D; Wang L; Ramezi A; Rendo P; Walters MC; Levasseur D; Peters R; Harris T; Hicks A
    Sci Rep; 2024 Oct; 14(1):24298. PubMed ID: 39414860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
    Brendel C; Guda S; Renella R; Bauer DE; Canver MC; Kim YJ; Heeney MM; Klatt D; Fogel J; Milsom MD; Orkin SH; Gregory RI; Williams DA
    J Clin Invest; 2016 Oct; 126(10):3868-3878. PubMed ID: 27599293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic base editing of human hematopoietic stem cells.
    Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
    Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
    Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
    Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
    N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 Editing of the
    Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
    N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene editing without
    Zeng J; Nguyen MA; Liu P; Ferreira da Silva L; Lin LY; Justus DG; Petri K; Clement K; Porter SN; Verma A; Neri NR; Rosanwo T; Ciuculescu MF; Abriss D; Mintzer E; Maitland SA; Demirci S; Tisdale JF; Williams DA; Zhu LJ; Pruett-Miller SM; Pinello L; Joung JK; Pattanayak V; Manis JP; Armant M; Pellin D; Brendel C; Wolfe SA; Bauer DE
    bioRxiv; 2023 May; ():. PubMed ID: 37292647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression analysis data of BCL11A and γ-globin genes in KU812 and KG-1 cell lines after CRISPR/Cas9-mediated BCL11A enhancer deletion.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Buch T; Karimipoor M
    Data Brief; 2020 Feb; 28():104974. PubMed ID: 31890812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.
    Li C; Georgakopoulou A; Mishra A; Gil S; Hawkins RD; Yannaki E; Lieber A
    Blood Adv; 2021 Feb; 5(4):1122-1135. PubMed ID: 33620431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of γ/β Globin Gene Switching in CD 34
    Taghavi SA; Hosseini KM; Tamaddon G; Kasraian L
    Indian J Hematol Blood Transfus; 2019 Oct; 35(4):758-764. PubMed ID: 31741633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.